RVL Pharmaceuticals Toekomstige groei
Future criteriumcontroles 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for RVL Pharmaceuticals.
Belangrijke informatie
n/a
Groei van de winst
n/a
Groei van de winst per aandeel
| Pharmaceuticals winstgroei | 23.7% |
| Inkomstengroei | n/a |
| Toekomstig rendement op eigen vermogen | n/a |
| Dekking van analisten | None |
| Laatst bijgewerkt | n/a |
Recente toekomstige groei-updates
Recent updates
RVL Pharmaceuticals plc (NASDAQ:RVLP) Analysts Just Cut Their EPS Forecasts Substantially
Aug 16
Analysts Just Made A Major Revision To Their RVL Pharmaceuticals plc (NASDAQ:RVLP) Revenue Forecasts
May 13RVL Pharmaceuticals plc (NASDAQ:RVLP) Doing What It Can To Lift Shares
May 12RVL Pharmaceuticals (NASDAQ:RVLP) Is Making Moderate Use Of Debt
Apr 20Is RVL Pharmaceuticals (NASDAQ:RVLP) Using Debt Sensibly?
Jan 05RVL Pharmaceuticals sees Q3 net sales of UPNEEQ for eye treatment about $10M
Oct 18RVL Pharmaceuticals: Chapter 2 - A Developing Quandary
Sep 22RVL Pharma in pact with Revision Skincare to broaden access to products
Aug 30GAAP EPS of -$0.14 beats by $0.07, revenue of $8.45M misses by $0.07M
Aug 11RVL Pharma posts preliminary 42% sales growth for eye treatment
Jul 07RVL Pharmaceuticals (NASDAQ:RVLP) Is Carrying A Fair Bit Of Debt
Jul 04RVL Pharmaceuticals: Chapter 1 Gives A Mixed Picture
Jun 15New Forecasts: Here's What Analysts Think The Future Holds For RVL Pharmaceuticals plc (NASDAQ:RVLP)
Apr 01RVL Pharmaceuticals: A Makeover For An Ugly Duckling
Mar 30Osmotica: A Different Breed Of Cat
Dec 14Osmotica Pharmaceuticals (NASDAQ:OSMT) Takes On Some Risk With Its Use Of Debt
Aug 20Osmotica: Paring Down, Focusing On UPNEEQ
Jul 16In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat RVL Pharmaceuticals onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.
Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.
Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 6/30/2023 | 37 | -68 | -47 | -44 | N/A |
| 3/31/2023 | 37 | -56 | -32 | -30 | N/A |
| 12/31/2022 | 50 | -52 | -39 | -38 | N/A |
| 9/30/2022 | 43 | -53 | -46 | -46 | N/A |
| 6/30/2022 | 35 | -66 | -52 | -52 | N/A |
| 3/31/2022 | 38 | -76 | -58 | -57 | N/A |
| 12/31/2021 | 18 | -83 | -49 | -55 | N/A |
| 9/30/2021 | 16 | -115 | -34 | -39 | N/A |
| 6/30/2021 | 40 | -86 | -9 | -13 | N/A |
| 3/31/2021 | 28 | -82 | 11 | 6 | N/A |
| 12/31/2020 | 28 | -89 | 15 | 18 | N/A |
| 9/30/2020 | 87 | -64 | 23 | 27 | N/A |
| 6/30/2020 | 126 | -178 | 51 | 54 | N/A |
| 3/31/2020 | 183 | -285 | 35 | 40 | N/A |
| 12/31/2019 | 240 | -271 | 30 | 34 | N/A |
| 9/30/2019 | 246 | -351 | 59 | 63 | N/A |
| 6/30/2019 | 247 | -243 | 29 | 33 | N/A |
| 3/31/2019 | 261 | -112 | 21 | 24 | N/A |
| 12/31/2018 | 264 | -110 | 33 | 38 | N/A |
| 9/30/2018 | 274 | -1 | 14 | 29 | N/A |
| 6/30/2018 | 262 | -10 | 3 | 19 | N/A |
| 3/31/2018 | 248 | -31 | 27 | 45 | N/A |
| 12/31/2017 | 246 | -41 | 38 | 58 | N/A |
| 12/31/2016 | 218 | -42 | N/A | -45 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: Insufficient data to determine if RVLP.Q's forecast earnings growth is above the savings rate (2.5%).
Winst versus markt: Insufficient data to determine if RVLP.Q's earnings are forecast to grow faster than the US market
Hoge groeiwinsten: Insufficient data to determine if RVLP.Q's earnings are expected to grow significantly over the next 3 years.
Omzet versus markt: Insufficient data to determine if RVLP.Q's revenue is forecast to grow faster than the US market.
Hoge groei-inkomsten: Insufficient data to determine if RVLP.Q's revenue is forecast to grow faster than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if RVLP.Q's Return on Equity is forecast to be high in 3 years time